BIOSCIENCE firm Oxford Immunotec, which has developed a breakthrough test for TB, saw revenue jump 36 per cent to £19.7m, for the three months ended June 30.

The bulk of growth for the Milton Park-based company came from the United States, where revenues were up 65 per cent.

The firm is also having success with its tests for tick-borne disease.

Chief executive Dr Peter Wrighton-Smith said: “We delivered a strong second quarter with revenue growth that exceeded the top end of our guidance range.

“As we continue our evolution from a single- to a multi-product company, we are pleased to see solid growth in our core TB business as well as a strong contribution from our accelerating tick-borne disease franchise.”